This Gastro Bites session is your exclusive opportunity to get insight and ask questions from the authors of the recent AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases — the first comprehensive guideline on the use of fecal microbiota-based therapies in GI diseases.

Fecal microbiota–based therapies include conventional fecal microbiota transplant and U.S. Food and Drug Administration–approved therapies, fecal microbiota live-jslm and fecal microbiota spores live-brpk. AGA’s guideline provides clinicians with recommendations on the use of fecal microbiota–based therapies in adults with recurrent Clostridioides difficile (C. diff) infection; severe to fulminant C. diff infection; inflammatory bowel diseases, including pouchitis; and irritable bowel syndrome.

Learning objectives:

Guideline authors will share best practices and discuss:

• Fecal microbiota–based therapies to prevent recurrent C. diff in select patients.
• Conventional fecal microbiota transplant treatment for select adults hospitalized with severe or fulminant C. diff infection not responding to standard-of-care antibiotics.
• Refraining from recommending fecal microbiota transplants for gastrointestinal conditions.

Speakers:

Dina Kao, MD, FRCPC
Professor of Medicine
Director, Edmonton FMT program
Division of Gastroenterology
University of Alberta

Byron P. Vaughn, MD, MS, AGAF
Associate Professor of Medicine
Co-director, Inflammatory Bowel Disease Program
Division of Gastroenterology, Hepatology, and Nutrition 
University of Minnesota 

Colleen Kelly, MD, AGAF
Member of the Faculty, Department of Medicine
Brigham and Women’s Hospital

Pricing:

Member	Nonmember
Free	Free

Original release date: July 23, 2024

Expiration date: July 24, 2026